Single-Dose HPV Vaccine Evaluation Consortium

Results are emerging from several clinical trials evaluating the ability of a single dose of HPV vaccine to elicit a strong immune response against incident and persistent HPV infections, which are the necessary prerequisites to development of cervical lesions and in the longer term, cervical cancer.

The data accumulated to date support the World Health Organization (WHO) endorsement of a single-dose HPV vaccination schedule for substantially reducing the incidence of HPV-attributable cervical precancer and cancer for the primary target of girls aged 9-14 years old and for young women aged 15-20 years old.

Explore and share the evidence using the resources below.

Fact sheet: Evidence on single-dose HPV
This two-page brief provides a snapshot of the evidence supporting WHO’s endorsement of a single-dose HPV vaccination schedule.

Slide deck:
This PowerPoint deck outlines the evidence base in support of a single-dose vaccination schedule. Use the presentation as a guide for meetings with key decision-makers.

2022 Evidence Review:
The 2022 Evidence Review by the Single-Dose HPV Evaluation Consortium collated, synthesized, and evaluated evidence that contributed to the WHO SAGE endorsement of a single-dose HPV vaccination schedule in the primary target group.

• Read the five-page general summary.
• Read the 30-page technical synthesis of the HPV Single Dose Consortium’s full review of current, published evidence relevant to single-dose HPV vaccination. This includes immunogenicity, efficacy and effectiveness; identification of gaps in the evidence; and forthcoming evidence.
• Read the full text of the Evidence Review.

World Health Organization updated position paper on HPV vaccination schedules, December 2022

WHO Strategic Advisory Group of Experts on Immunization (SAGE) endorsement of a single-dose HPV vaccination schedule, April 2022

• Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania. Vaccine. January 2023.

• Efficacy of single-dose HPV vaccination among young African women. NEJM Evidence. April 2022

• Immunogenicity and Safety Results Comparing Single Dose Human Papillomavirus Vaccine with Two or Three Doses in Tanzanian Girls - the DoRIS Randomised Trial. Preprint. March 2022.

• Comparison of Immune Responses after One Dose of HPV Vaccine in a Dose-Reduction HPV Vaccine Trial in Adolescent Girls in Tanzania to the Costa Rica Vaccine and India HPV Vaccine Trials. Preprint. March 2022.

• Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncology. November 2021.

• Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute. October 2020.

• Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine. February 2021.

• Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. Human Vaccines & Immunotherapeutics. December 2019.

• Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. December 2019.

• Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. The Journal of Infectious Diseases. November 2019.

• Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. The Lancet Oncology. November 2019, Volume 20, Issue 11, Pages e637-e644

• Preventing Cervical Cancer: How much HPV Vaccine do we need? Vaccine. August 2018, Volume 36, Issue 32, Part A, Pages 4759-4836

• Can we use one dose of HPV vaccine to ensure long term protection? HPV World. September 2017, Year 1, No 23-31.